• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

Article

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda). The FDA has approved the drug for use as first-line treatment in a select population of patients whose tumors have been assessed for PD-L1 expression using an FDA-approved test.

The expanded approval, which comes less than 2 months after Merck filed a supplemental Biologics Application for pembrolizumab, adds the following indications:

  1. Patients with metastatic NSCLC whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] greater than or equal to 50%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations and no prior systemic chemotherapy treatment for metastatic NSCLC.
  2. Patients with metastatic NSCLC whose tumors express PD-L1 (TPS greater than or equal to 1%), as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab.

Based on the data submitted by the company, the recommended dose for pembrolizumab is 200 mg intravenously, every 3 weeks.

Related Videos
Dr Guru Sonpavde
dr amy laughlin
dr kathi mooney
dr saira jan
dr saira jan
Ted Okon, MBA, Community Oncology Alliance
Miriam J. Atkins, MD, FACP, Community Oncology Alliance/AO Multispecialty Clinic
Lalan Wilfongd, MD, US Oncology Network
dr erin gillaspie
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.